Top Markets
#1 Black Phoenix Black Phoenix +354.68%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +68.84%
#4 OpenEden OpenEden +62.66%
#5 Akedo Akedo +55.50%
#6 BasedHype BasedHype +26.50%
#7 Cryptopia Cryptopia +21.54%
#8 Avantis Avantis +20.20%
#9 Humanity Humanity +19.73%
#10 Ether.fi Ether.fi +17.74%
Coin of the day
Black Phoenix Black Phoenix
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Synairgen plc Synairgen plc

Synairgen plc

SNG
Rang în acțiuni #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Preț acțiune
$0.01292666
Ultima sincronizare: 2025-04-08
Capitalizare de piață
$157.54K
Schimbare (1 zi)
6.84%
Schimbare (1 an)
0.00%
Țară
GB
Tranzacționează Synairgen plc (SNG)

Categorie

Healthcare
Raport P/B pentru Synairgen plc (SNG)
Raport P/B la data de August 2026 TTM: 0.15
Conform celor mai recente rapoarte financiare și prețului acțiunilor Synairgen plc, raportul P/B actual (TTM) este 0.15. La sfârșitul anului 2022, compania avea un P/B de 0.97.
Istoricul raportului P/B pentru Synairgen plc din 2004 până în 2026
Raport P/B la sfârșitul fiecărui an
An Raport P/B Schimbă
2026 (TTM) 0.15 -78.10%
2023 0.69 -29.11%
2022 0.97 -88.10%
2021 8.13 326.23%
2020 1.91 -7.27%
2019 2.06 -99.86%
2018 1.50K 26.76%
2017 1.18K -39.85%
2016 1.97K -1.83%
2015 2.01K -7.72%
2014 2.17K 11,509.79%
2013 18.72 170.50%
2012 6.92 224.88%
2011 2.13 16.99%
2010 1.82 206.96%
2009 0.59 -73.97%
2008 2.28 35.55%
2007 1.68 -99.48%
2006 322.75 18.54%
2005 272.28 1,051.93%
2004 23.64 0.00%
Raport P/B pentru companii similare sau competitoare
Companie Raport P/B Diferență raport P/B Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 4,043.81%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 4,101.39%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 2,305.03%
BE